ArticleThe clinical respiratory journal2026
Pulmonary Surfactant Treatment for Preterm Infants With Respiratory Distress Syndrome: A Nationwide Survey.
Article in The clinical respiratory journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPulmonary surfactant is essential for neonatal respiratory distress syndrome (RDS) management, yet national data on how surfactant is used in China are limited. We surveyed current practices and variation in surfactant availability and administration.
methodsIn October-December 2022, a nationwide cross-sectional online survey was completed by one neonatologist from each of 394 hospitals across 30 provinces. Items covered surfactant availability (including delivery room access), product selection, dosing, timing, and administration techniques.
resultsSurfactant was available in 96.7% of hospitals; poractant alfa and calsurf were available in 88.6% and 58.1%, respectively. Only 51.6% of hospitals reported surfactant availability in delivery rooms. For the first dose, 200 mg/kg was preferred for poractant alfa (68.8%) and 100 mg/kg for calsurf (63.8%). The reported median time to first dose was 2.0 h after birth; poractant alfa was administered sooner than calsurf (10 vs. 30 min estimated administration time; p < 0.001). Most respondents (79.7%) reported giving surfactant after noninvasive ventilation failure in infants who subsequently required mechanical ventilation, with higher use in tertiary vs. secondary hospitals (82.1% vs. 71.7%; p = 0.03). Intubation-surfactant-extubation (INSURE) and less invasive surfactant administration (LISA)/minimally invasive surfactant therapy (MIST) were available in 86.5% and 49.7% of hospitals, respectively. Additionally, 25.1% of the respondents reported combining a surfactant with glucocorticoids for treating RDS.
conclusionSurfactant use in China shows substantial between-hospital variation, particularly in delivery room access and less invasive administration. Standardized training and improved resource allocation may reduce disparities and support timely, evidence-based surfactant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.